Seal Rock Therapeutics
October 17, 2023
Proven, clinical stage company discovering and developing first-in-class kinase inhibitors for diseases of the liver, kidney, and CNS. Lead program is phase 2-ready and will be evaluated in liver and/or kidney diseases. Recent $107 deal with Genfit, who will develop an IV formulation of Seal Rock's clinical-stage kinase inhibitor for acute-on-chronic liver disease.
CEO/Top Company Official
Lead Product in Development
SRT-015. Completed phase 1 healthy volunteer trial with no safety issues identified
Number Of Unlicensed Products
One - SRT-015. In addition, this funding round will support CNS program to the point that multiple strategics would be ready to partner if data are positive